Company Overview

Evotec SE is a Germany-based drug discovery and development company operating within the biopharmaceutical and life sciences industries. The company specializes in providing integrated research and development (R&D) services and co-developing proprietary drug candidates in partnership with pharmaceutical and biotechnology companies. Its business model combines fee-for-service research with long-term value creation through milestone payments, royalties, and equity participation in partnered drug programs.

Founded in 1993 as Evotec BioSystems GmbH, the company initially focused on assay development and high-throughput screening technologies. Over time, Evotec evolved into a broad-based R&D platform provider through organic growth and strategic acquisitions, expanding into biologics, data-driven drug discovery, and end-to-end drug development. Its positioning is differentiated by scale, automation, and an industrialized approach to early-stage drug discovery, enabling it to serve both large pharmaceutical companies and smaller biotechnology firms.

Business Operations

Evotec operates through two primary business segments: Shared R&D and Just – Evotec Biologics. The Shared R&D segment generates revenue through integrated discovery and development services, strategic alliances, and co-creation partnerships that include upfront payments, research funding, milestones, and downstream royalties. The Just – Evotec Biologics segment focuses on the development and manufacturing of biologics using continuous bioprocessing technologies, providing services from cell line development to clinical and commercial manufacturing.

The company conducts operations across discovery, preclinical research, and selected clinical development stages. Evotec controls proprietary platforms in automation, artificial intelligence-supported data analytics, induced pluripotent stem cell (iPSC) technology, and biologics manufacturing. It maintains long-term partnerships with major pharmaceutical companies, including strategic alliances structured around therapeutic areas, and operates through wholly owned subsidiaries rather than joint ventures in most cases.

Strategic Position & Investments

Evotec’s strategic direction emphasizes scalable, technology-driven drug discovery, expansion of biologics capabilities, and increased participation in downstream drug value. Growth initiatives include investment in automated laboratories, data integration platforms, and expansion of biologics manufacturing capacity through Just – Evotec Biologics. The company has also pursued selective acquisitions to strengthen capabilities, including Just Biotherapeutics and Aptuit, both of which expanded Evotec’s biologics and development services offerings.

Evotec maintains a portfolio of partnered drug programs across therapeutic areas such as neuroscience, oncology, metabolic diseases, and infectious diseases. The company has established numerous long-term strategic alliances that provide shared economics rather than pure service revenue. Emerging areas of focus include data-centric drug discovery, biologics optimization, and industrial-scale manufacturing technologies.

Geographic Footprint

Evotec is headquartered in Hamburg, Germany, and operates a global network of research and development sites across Europe, North America, and Asia. Major operational hubs are located in Germany, France, the United Kingdom, and the United States, with biologics manufacturing facilities in Seattle, Washington, and additional R&D sites in Redmond, Washington, and Toulouse, France.

The company’s international presence supports collaborations with global pharmaceutical partners and enables access to diverse scientific talent pools. Evotec’s investments and operations give it a significant footprint in both European and U.S. biopharmaceutical markets, with growing influence in biologics manufacturing and integrated drug discovery services worldwide.

Leadership & Governance

Evotec is led by an executive team with backgrounds in pharmaceuticals, biotechnology, and industrial R&D. The leadership emphasizes a long-term, partnership-driven strategy focused on scientific excellence, automation, and shared value creation with collaborators. Governance follows German corporate standards with a management board and supervisory board structure.

Key executives include:

• Christian Wojczewski – Chief Executive Officer
• Enno Spillner – Chief Financial Officer
• Cord Dohrmann – Chief Scientific Officer
• Craig Johnstone – Chief Operating Officer
• Werner Lanthaler – Founder and former Chief Executive Officer